Chen Q, Zheng R S, Zhang S K, Zhang S W, Liu S Z, Sun X B, Wei W W, He J
Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, China.
Cancer Registry Office, National Cancer Center/National Clinical Research Center for Cancer/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1001-1006. doi: 10.3760/cma.j.cn112152-20200309-00184.
To estimate cancer incidence and mortality of kidney and unspecified urinary organs in China using cancer registry data in 2015. The cancer registry data from 501 local cancer registries in China were collected, checked and assessed based on the criteria of data quality control of the National Central Cancer Registry of China (NCCRC), and data from 368 registries were qualified for the analysis. Cancer incidence and mortality rates of kidney and unspecified urinary organs stratified by geographical location (eastern, middle, western areas), gender, age groups were calculated. Population data of 2015 was used to estimate the cancer cases and deaths of kidney and unspecified urinary organs in China. Chinese standard population in 2000 and Segi's world population were used for the calculation of age-standardized incidence and mortality rates. A total of 74.2 thousand new cancer cases of kidney and unspecified urinary organs were diagnosed in 2015, 46.9 thousand of them were male, while 27.3 thousand were female, with a crude incidence rate of 5.40/10(5). The age-standardized incidence rates by Chinese (ASIRC) and world standard population (ASIRW) were 3.57/10(5) and 3.56/10(5), respectively. A total of 53.4 thousand and 20.8 thousand new cases were diagnosed in urban and rural area, with incidence rates of 6.93/10(5) and 3.45/10(5), respectively. The ASIRC of urban area was higher than that of rural area. There were 39.2 thousand, 20.6 thousand, and 14.4 thousand new cases diagnosed in eastern, middle, and western areas of China, respectively. The crude incidence rates were 7.60/10(5), 4.47/10(5), and 3.63/10(5), respectively, with a descend ASIRC of each area. A total of 27.1 thousand death cases reported, of them 16.9 thousand were male, while 10.2 thousand were female, with a crude mortality rate of 1.97/10(5), both of the ASIRC and ASMRW were 1.21/10(5). The deaths of urban and rural area were 19.5 thousand and 7.6 thousand cases, with the crude mortality rates of 2.53/10(5) and 1.26/10(5), respectively. The ASIRC of urban area was higher than that of rural area. There were 13.4 thousand, 8.4 thousand, and 5.1 thousand death cases reported in eastern, middle, and western areas, respectively, the crude mortality rates were 2.61/10(5), 1.83/10(5) and 1.30/10(5), respectively, with a descend ASIRC of each area. The disease burden of kidney cancer differs between urban area and rural area, and differs among eastern, middle, and western areas of China, therefore, different prevent and treatment strategies should be taken in different areas of China.
利用2015年癌症登记数据估算中国肾脏及未特指泌尿器官的癌症发病率和死亡率。收集了中国501个地区癌症登记处的癌症登记数据，并依据中国国家癌症中心（NCCRC）的数据质量控制标准进行检查和评估，其中368个登记处的数据符合分析要求。计算了按地理位置（东部、中部、西部地区）、性别、年龄组分层的肾脏及未特指泌尿器官的癌症发病率和死亡率。采用2015年的人口数据估算中国肾脏及未特指泌尿器官的癌症病例数和死亡数。使用2000年中国标准人口和Segi世界人口计算年龄标准化发病率和死亡率。2015年共诊断出74200例肾脏及未特指泌尿器官的新发癌症病例，其中男性46900例，女性27300例，粗发病率为5.40/10万。中国标准人口年龄标准化发病率（ASIRC）和世界标准人口年龄标准化发病率（ASIRW）分别为3.57/10万和3.56/10万。城市和农村地区分别诊断出53400例和20800例新病例，发病率分别为6.93/10万和3.45/10万。城市地区的ASIRC高于农村地区。中国东部、中部和西部地区分别诊断出39200例、20600例和14400例新病例，粗发病率分别为7.60/10万、4.47/10万和3.63/10万，各地区的ASIRC呈下降趋势。共报告27100例死亡病例，其中男性16900例，女性10200例，粗死亡率为1.97/10万，ASIRC和世界标准人口年龄标准化死亡率（ASMRW）均为1.21/10万。城市和农村地区的死亡病例分别为19500例和7600例，粗死亡率分别为2.53/10万和1.26/10万。城市地区的ASIRC高于农村地区。东部、中部和西部地区分别报告13400例、8400例和5100例死亡病例，粗死亡率分别为2.61/10万、1.83/10万和1.30/10万，各地区的ASIRC呈下降趋势。肾癌的疾病负担在城市和农村地区存在差异，在中国东部、中部和西部地区也存在差异，因此，中国不同地区应采取不同的预防和治疗策略。
